Had to go way back to find some levels to plot against and 2017 looks like it's the mark. The interesting part is that this 236 area has been an area of traffic in the past. Considering that
PAVM
failed to break and hold (for now) once again might reinforce that idea. Prior to reaching those highs, the stock tested this area a few more times but failed at every pass besides 1.
"The progress from Lucid is one aspect that traders are watching with PAVmed. However, an earlier development this summer may have also acted as a catalyst for the record-setting move in 2021. Once again, this involves Lucid’s EsoGuard test. It received a European CE mark certification. This now allows the test to be marketed in numerous European countries...While PAVmed isn’t developing a cancer treatment, the EsoGuard platform is the first step to potential prevention. According to the company, it is the first and only commercially available diagnostic test capable of widespread screening to prevent esophageal cancer deaths through early detection of esophageal precancer and cancer in at-risk chronic heartburn patients."
Quote Source: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
PAVM
failed to break and hold (for now) once again might reinforce that idea. Prior to reaching those highs, the stock tested this area a few more times but failed at every pass besides 1. "The progress from Lucid is one aspect that traders are watching with PAVmed. However, an earlier development this summer may have also acted as a catalyst for the record-setting move in 2021. Once again, this involves Lucid’s EsoGuard test. It received a European CE mark certification. This now allows the test to be marketed in numerous European countries...While PAVmed isn’t developing a cancer treatment, the EsoGuard platform is the first step to potential prevention. According to the company, it is the first and only commercially available diagnostic test capable of widespread screening to prevent esophageal cancer deaths through early detection of esophageal precancer and cancer in at-risk chronic heartburn patients."
Quote Source: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day